An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension.
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Aliskiren (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Jun 2011 Pooled pharmacodynamic analysis results assessing the effect of treatment on plasma renin activity published in the Journal of Clinical Pharmacology.
- 09 Jun 2011 New trial record